A phase Ib/IIa clinical trial assessing efficacy, safety and tolerability of ACP-103 in patients with Parkinson′s disease.
Phase of Trial: Phase I/II
Latest Information Update: 09 May 2016
At a glance
- Drugs Pimavanserin (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Therapeutic Use
- 09 May 2016 New trial record